Autonomix Medical, Inc. 8-K

What Happened
Autonomix Medical, Inc. (AMIX) announced in an 8-K that on January 14, 2026 it received a deficiency letter from the Nasdaq Listing Qualifications Staff notifying the company that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Nasdaq has provided an initial 180-calendar-day compliance period under Rule 5810(c)(3)(A), giving the company until July 13, 2026 to regain compliance.

Key Details

• Deficiency letter dated January 14, 2026 for failure to meet the $1.00 minimum closing bid price (30 consecutive business days).
• Company has until July 13, 2026 (180 days) to regain compliance; regaining compliance requires a closing bid of $1.00+ for at least 10 consecutive business days (subject to Staff discretion).
• If not cured, the company may be eligible for a second 180-day period only if it meets other Nasdaq listing standards (market value of publicly held shares and initial listing standards) and notifies Nasdaq of its intent to cure (which could include a reverse stock split).
• If still noncompliant after available remedies, Nasdaq could move to delist; the company may appeal to a Nasdaq Listing Qualifications Panel.

Why It Matters
A Nasdaq deficiency notice signals a risk of delisting if the company cannot restore its share price to meet Nasdaq’s minimum bid requirement. Delisting or the need to implement measures such as a reverse stock split can affect liquidity, investor perception, and the trading behavior of the stock. Autonomix says it will monitor its closing bid and may consider options to regain compliance, but there is no assurance it will succeed.